Anti-vegf cancer therapy in nephrology practice

International Journal of Nephrology

Volumn 2014, Issue , 2014, Pages

  Izzedine, Hassan ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Monceau Park International Clinic   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926637828     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2014/143426     Document Type: Review

References (74)

1. H. F. Dvorak, "Angiogenesis: update 2005," Journal of Trombo-sis and Haemostasis, vol. 3, no. 8, pp. 1835-1842, 2005.
2. S. V. Bhadada, B. R. Goyal, and M. M. Patel, "Angiogenic targets for potential disorders," Fundamental and Clinical Pharmacology, vol. 25, no. 1, pp. 29-47, 2011.
3. J. Müller-Deile, K. Worthmann, M. Saleem, I. Tossidou, H. Haller, and M. Schifer, "The balance of autocrine VEGF-A and VEGF-C determines podocyte survival," American Journal of Physiology-Renal Physiology, vol. 297, no. 6, pp. F1656-F1667, 2009.
4. H. Izzedine, C. Massard, J. P. Spano, F. Goldwasser, D. Khayat, and J. C. Soria, "VEGF signalling inhibition-induced protein-uria: mechanisms, signifcance and management," European Journal of Cancer, vol. 46, no. 2, pp. 439-448, 2010.
5. R. K. Barakat, N. Singh, R. Lal, R. R. Verani, K. W. Finkel, and J. R. Foringer, "Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma," Annals of Pharma-cotherapy, vol. 41, no. 4, pp. 707-710, 2007.
6. V. Eremina, M. Sood, J. Haigh et al., "Glomerular-specifc alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases," The Journal of Clinical Investigation, vol. 111, no. 5, pp. 707-716, 2003.
7. B. F. Schrijvers, A. Flyvbjerg, and A. S. de Vriese, "The role of vascular endothelial growth factor (VEGF) in renal pathophys-iology," Kidney International, vol. 65, no. 6, pp. 2003-2017, 2004.
8. V. Eremina, J. A. Jeferson, J. Kowalewska et al., "VEGF inhibition and renal thrombotic microangiopathy," The New England Journal of Medicine, vol. 358, no. 11, pp. 1129-1136, 2008.
9. D. C. Sane, L. Anton, and K. B. Brosnihan, "Angiogenic growth factors and hypertension," Angiogenesis, vol. 7, no. 3, pp. 193-201, 2004.
10. W. J. van Heeckeren, J. Ortiz, M. M. Cooney, and S. C. Remick, "Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?" Journal of Clinical Oncology, vol. 25, no. 21, pp. 2993-2995, 2007.
11. J. C. Soria, C. Massard, and H. Izzedine, "From theoretical synergy to clinical supra-additive toxicity," Journal of Clinical Oncology, vol. 27, no. 9, pp. 1359-1361, 2009.
12. H. Hurwitz and S. Saini, "Bevacizumab in the treatment of metastatic colorectal cancer: safety profle and management of adverse events," Seminars in Oncology, vol. 33, no. 10, pp. S26-S34, 2006.
13. F. F. Kabbinavar, J. Schulz, M. McCleod et al., "Addition of bevacizumab to bolus fuorouracil and leucovorin in frst-line metastatic colorectal cancer: Results of a randomized phase II trial," Journal of Clinical Oncology, vol. 23, no. 16, pp. 3697-3705, 2005.
14. R. J. Motzer, B. I. Rini, R. M. Bukowski et al., "Sunitinib in patients with metastatic renal cell carcinoma," Journal of the American Medical Association, vol. 295, no. 21, pp. 2516-2524, 2006.
15. G. D. Demetri, A. T. van Oosterom, M. Blackstein et al., "Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST," Journal of Clinical Oncology, vol. 34, p. 308s, 2005, (Abstract 4000).
16. R. C. Kane, A. T. Farrell, H. Saber et al., "Sorafenib for the treatment of advanced renal cell carcinoma," Clinical Cancer Research, vol. 12, no. 24, pp. 7271-7278, 2006.
17. J. C. Yang, L. Haworth, R. M. Sherry et al., "A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer," The New England Journal of Medicine, vol. 349, no. 5, pp. 427-434, 2003.
18. M. L. Maitland et al., "Blood pressure (BP) as a biomarker for sorafenib, an inhibitor of the vascular endothelial growth factor (VEGF) signalling pathway [abstract]," ASCO Meeting Abstracts, vol. 24, p. 2035, 2035.
19. J. Drevs, P. Siegert, M. Medinger et al., "Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors," Journal of Clinical Oncology, vol. 25, no. 21, pp. 3045-3054, 2007.
20. O. Rixe, B. Billemont, and H. Izzedine, "Hypertension as a predictive factor of Sunitinib activity," Annals of Oncology, vol. 18, no. 6, p. 1117, 2007.
21. P. Bono, H. Elfving, T. Utriainen et al., "Hypertension and clinical beneft of bevacizumab in the treatment of advanced renal cell carcinoma," Annals of Oncology, vol. 20, no. 2, pp. 393-394, 2009.
22. A. Ravaud and M. Sire, "Arterial hypertension and clinical beneft of sunitinib, sorafenib and bevacizumab in frst and second-line treatment of metastatic renal cell cancer," Annals of Oncology, vol. 20, no. 5, pp. 966-967, 2009.
23. B. I. Rini, S. Halabi, J. E. Rosenberg et al., "Phase III trial of beva-cizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: fnal results of CALGB 90206," Journal of Clinical Oncology, vol. 28, no. 13, pp. 2137-2143, 2010.
24. G. Friberg, K. Kasza, E. E. Vokes, and H. L. Kindler, "Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G)," Journal of Clinical Oncology, vol. 23, p. 16S, 2005.
25. S. N. Holden, S. G. Eckhardt, R. Basser et al., "Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors," Annals of Oncology, vol. 16, no. 8, pp. 1391-1397, 2005.
26. B. I. Rini, J. H. Schiller, J. P. Fruehauf et al., "Association of diastolic blood pressure (dBP) 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736)," Journal of Clinical Oncology, vol. 26, no. 20, abstract 3543, 2008.
27. H. Hurwitz, P. S. Douglas, J. P. Middleton et al., "Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV)," Journal of Clinical Oncology, vol. 28, no. 15s, 2010.
28. J. D. Hood, C. J. Meininger, M. Ziche, and H. J. Granger, "VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells," American Journal of Physiology: Heart and Circulatory Physiology, vol. 274, no. 3, pp. H1054-H1058, 1998.
29. J. R. Horowitz, A. Rivard, R. van der Zee et al., "Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension: Evidence for a maintenance role in quiescent adult endothelium," Arteriosclerosis, Trombosis, and Vascular Biology, vol. 17, no. 11, pp. 2793-2800, 1997.
30. C. S. Facemire, A. B. Nixon, R. Grifths, H. Hurwitz, and T. M. Cofman, "Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression," Hypertension, vol. 54, no. 3, pp. 652-658, 2009.
31. A. Nixon, J. Allen, E. Miller et al., "Clinical evaluation of nitric oxide responses to anti-VEGF therapy with bevacizumab," Journal of Clinical Oncology, vol. 25, no. 18S, 2007.
32. N. Steeghs, M. Hovens, and A. Rabelink, "VEGFr2 blockade in patients with solid tumors: mechanisms of hypertension and efects on vascular function," Journal of Clinical Oncology, vol. 24, abstract 3037, no. 130s, 2006.
33. B. Escudier, T. Eisen, W. M. Stadler et al., "Sorafenib in advanced clear-cell renal-cell carcinoma," The New England Journal of Medicine, vol. 356, no. 2, pp. 125-134, 2007.
34. J. M. Llovet, S. Ricci, V. Mazzaferro et al., "Sorafenib in advanced hepatocellular carcinoma," New England Journal of Medicine, vol. 359, no. 4, pp. 378-390, 2008.
35. G. D. Demetri, A. T. van Oosterom, C. R. Garrett et al., "Efcacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour afer failure of imatinib: a randomised controlled trial," The Lancet, vol. 368, no. 9544, pp. 1329-1338, 2006.
36. R. J. Motzer, T. E. Hutson, P. Tomczak et al., "Sunitinib versus interferon alfa in metastatic renal-cell carcinoma," The New England Journal of Medicine, vol. 356, no. 2, pp. 115-124, 2007.
37. B. P. Schneider, M. Wang, M. Radovich et al., "Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus beva-cizumab in advanced breast cancer: ECOG 2100," Journal of Clinical Oncology, vol. 26, no. 28, pp. 4672-4678, 2008.
38. K. Eechoute, A. A. M. van der Veldt, S. Oosting et al., "Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension," Clinical Pharmacology and Terapeutics, vol. 92, no. 4, pp. 503-510, 2012.
39. J. A. Allen, A. Adlakha, and P. R. Bergethon, "Reversible posterior leukoencephalopathy syndrome afer bevacizumab/FOLFIRI regimen for metastatic colon cancer," Archives of Neurology, vol. 63, no. 10, pp. 1475-1478, 2006.
40. R. Govindarajan, J. Adusumilli, D. L. Baxter, A. El-Khoueiry, and S. I. Harik, "Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006," Journal of Clinical Oncology, vol. 24, no. 28, article e48, 2006.
41. A. V. Chobanian, G. L. Bakris, H. R. Black et al., "National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report," Journal of the American Medical Association, vol. 289, pp. 2560-2572, 2003.
42. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., "Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer," The New England Journal of Medicine, vol. 350, no. 23, pp. 2335-2342, 2004.
43. K. Miller, M. Wang, J. Gralow et al., "Paclitaxel plus beva-cizumab versus paclitaxel alone for metastatic breast cancer," The New England Journal of Medicine, vol. 357, no. 26, pp. 2666-2676, 2007.
44. B. J. Giantonio, P. J. Catalano, N. J. Meropol et al., "Bevacizumab in combination with oxaliplatin, fuorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200," Journal of Clinical Oncology, vol. 25, no. 12, pp. 1539-1544, 2007.
45. A. Sandler, R. Gray, M. C. Perry et al., "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer," The New England Journal of Medicine, vol. 355, no. 24, pp. 2542-2550, 2006.
46. B. Escudier, A. Pluzanska, P. Koralewski et al., "Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial," The Lancet, vol. 370, no. 9605, pp. 2103-2111, 2007.
47. Avastin, (bevacizumab) package insert, Genentech Inc., 2008.
48. X. Zhu, S. Wu, W. L. Dahut, and C. R. Parikh, "Risks of protein-uria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis," The American Journal of Kidney Diseases, vol. 49, no. 2, pp. 186-193, 2007.
49. O. Rixe, R. M. Bukowski, M. D. Michaelson et al., "Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study," The Lancet Oncology, vol. 8, no. 11, pp. 975-984, 2007.
50. T. Kamba, B. Y. Y. Tam, H. Hashizume et al., "VEGF-dependent plasticity of fenestrated capillaries in the normal adult micro-vasculature," The American Journal of Physiology: Heart and Circulatory Physiology, vol. 290, no. 2, pp. H560-H576, 2006.
51. H. Izzedine, J. C. Soria, and B. Escudier, "Proteinuria and VEGF-targeted therapies: an underestimated toxicity?" Journal of Nephrology, vol. 26, no. 5, pp. 807-810, 2013.
52. C. Frangié, C. Lefaucheur, J. Medioni, C. Jacquot, G. S. Hill, and D. Nochy, "Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma," The Lancet Oncology, vol. 8, no. 2, pp. 177-178, 2007.
53. D. Roncone, A. Satoskar, T. Nadasdy, J. P. Monk, and B. H. Rovin, "Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma," Nature Clinical Practice Nephrology, vol. 3, no. 5, pp. 287-293, 2007.
54. H. Izzedine, I. Brocheriou, G. Deray, and O. Rixe, "Trombotic microangiopathy and anti-VEGF agents," Nephrology Dialysis Transplantation, vol. 22, no. 5, pp. 1481-1482, 2007.
55. G. Bollée, N. Patey, G. Cazajous et al., "Trombotic microan-giopathy secondary to VEGF pathway inhibition by sunitinib," Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 682-685, 2009.
56. E. Kapiteijn, A. Brand, J. Kroep, and H. Gelderblom, "Suni-tinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome," Annals of Oncology, vol. 18, no. 10, pp. 1745-1747, 2007.
57. S. A. Levey, R. S. Bajwa, M. M. Picken, J. I. Clark, K. Barton, and D. J. Leehey, "Trombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation," NDT Plus, vol. 1, no. 3, pp. 154-156, 2008.
58. H. Izzedine, M. Mangier, V. Ory et al., "Expression patterns of RelA and c-mip are associated with diferent glomerular diseases following anti-VEGF therapy," Kidney International, vol. 85, no. 2, pp. 457-470, 2014.
59. D. R. Feldman, M. S. Baum, M. S. Ginsberg et al., "Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma," Journal of Clinical Oncology, vol. 27, no. 9, pp. 1432-1439, 2009.
60. H. Izzedine, O. Rixe, B. Billemont, A. Baumelou, and G. Deray, "Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension," American Journal of Kidney Diseases, vol. 50, no. 2, pp. 203-218, 2007.
61. H. Izzedine, S. Ederhy, F. Goldwasser et al., "Management of hypertension in angiogenesis inhibitor-treated patients," Annals of Oncology, vol. 20, no. 5, pp. 807-815, 2009.
62. A. Pande, J. Lombardo, E. Spangenthal, and M. Javle, "Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab," Anticancer Research, vol. 27, no. 5, pp. 3465-3470, 2007.
63. M. L. Veronese, A. Mosenkis, K. T. Flaherty et al., "Mechanisms of hypertension associated with BAY 43-9006," Journal of Clinical Oncology, vol. 24, no. 9, pp. 1363-1369, 2006.
64. S. Boehm, C. Rothermundt, D. Hess, and M. Joerger, "Antian-giogenic drugs in oncology: a focus on drug safety and the elderly-a mini-review," Gerontology, vol. 56, no. 3, pp. 303-309, 2010.
65. S. Geiger-Gritsch, B. Stollenwerk, R. Miksad, B. Guba, C. Wild, and U. Siebert, "Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials," Oncologist, vol. 15, no. 11, pp. 1179-1191, 2010.
66. E. S. Robinson, U. A. Matulonis, P. Ivy et al., "Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor," Clinical Journal of the American Society of Nephrology, vol. 5, no. 3, pp. 477-483, 2010.
67. S. Hapani, D. Chu, and S. Wu, "Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis," The Lancet Oncology, vol. 10, no. 6, pp. 559-568, 2009.
68. A. P. Hall, F. Russell Westwood, and P. F. Wadsworth, "Review of the efects of anti-angiogenic compounds on the epiphyseal growth plate," Toxicologic Pathology, vol. 34, no. 2, pp. 131-147, 2006.
69. O. Artunay, E. Yuzbasioglu, R. Rasier, A. Sengul, and H. Bahce-cioglu, "Posterior reversible encephalopathy syndrome afer intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy," Journal of Ocular Pharmacology and Terapeutics, vol. 26, no. 3, pp. 301-303, 2010.
70. Q. S. Chu, "Afibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors," Expert Opinion on Biological Terapy, vol. 9, no. 2, pp. 263-271, 2009.
71. J. S. Rudge, J. Holash, D. Hylton et al., "VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efcacious angiogenic blockade," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 47, pp. 18363-18370, 2007.
72. P. Bhargava and M. O. Robinson, "Development of second-generation VEGFR tyrosine kinase inhibitors: Current status," Current Oncology Reports, vol. 13, no. 2, pp. 103-111, 2011.
73. S. P. Ivy, J. Y. Wick, and B. M. Kaufman, "An overview of small-molecule inhibitors of VEGFR signaling," Nature Reviews Clinical Oncology, vol. 6, no. 10, pp. 569-579, 2009.
74. Y. Wu, Z. Zhong, J. Huber et al., "Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer," Clinical Cancer Research, vol. 12, no. 21, pp. 6573-6584, 2006.